Clinical trial
Effect on Liver Fat, Adipose Tissue and Metabolic Parameters When Switching a Protease Inhibitor or Efavirenz to Once Daily Raltegravir in HIV+ Patients With Body Mass Index Over 25 kg/m2 and With at Least One Metabolic Syndrome Component
NCT03374358 is registered in ClinicalTrials.gov with Helsinki University Central Hospital as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Effect on Liver Fat, Adipose Tissue and Metabolic Parameters When Switching a Protease Inhibitor or Efavirenz to Once Daily Raltegravir in HIV+ Patients With Body Mass Index Over 25 kg/m2 and With at Least One Metabolic Syndrome Component
- Lead sponsor
- Helsinki University Central Hospital
- Phase
- Phase 4
- Overall status
- Completed
- Start date
- January 10, 2018
- Completion date
- November 30, 2019
- Enrollment
- 45 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.